Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)

Ohlsson, V.; Baildam, Eileen; Foster, Helen; Jandial, Sharmila; Pain, Clare; Strike, Helen; Ramanan, A V

doi:10.1093/rheumatology/ken030

Cited by 51 publications

(32 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Anakinra plasma concentrations pedi core set criteria [34]. Recent data also support anakinra as second-line therapy for systemic-onset juvenile idiopathic arthritis, with six of seven patients from a case series in the UK experiencing rapid early improvement in systemic symptoms and joint disease [35]. Irigoyen et al [19] reported findings from a multicenter retrospective chart review of systemic-onset JRA patients (n=7) receiving anakinra.…”

Section: Discussionmentioning

confidence: 99%

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

et al. 2008

View full text Add to dashboard Cite

This study assessed the safety and preliminary efficacy of the interleukin-1 receptor antagonist anakinra in patients with polyarticular-course juvenile rheumatoid arthritis (JRA). Eighty-six patients entered a 12-week open-label run-in phase (1 mg/kg anakinra daily, ≤100 mg/day). Fifty responders were randomized to anakinra or placebo in a 16-week blinded phase, followed by a 12-month open-label extension (N=44). Due to low enrollment, the primary endpoint was changed from efficacy to safety. The incidence and nature of adverse events were similar across all study phases, with the exception of injection site reactions, which were mild to moderate and decreased with time. Anakinra produced a nonsignificant (P=0.11) reduction in disease flares compared with placebo. When normalized to 1 mg/kg dose, anakinra plasma concentrations were similar to values in adult patients with rheumatoid arthritis. These results indicate that anakinra 1 mg/kg once daily (≤100 mg/day) is safe and well tolerated in patients with JRA.

show abstract

Section: Discussionmentioning

confidence: 99%

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Anakinra, an interleukin 1 receptor antagonist, has been shown to effectively treat sJIA 1,2,3,4,5 ; however, some patients may require multiple painful daily injections to control their disease. Another biologic, abatacept, selectively modulates the CD80/CD86:CD28 costimulatory signal necessary for T cell activation 6 and has been shown to be effective in treating patients with sJIA who have a polyarticular course 7 .…”

Section: To the Editormentioning

confidence: 99%

Combination Therapy of Abatacept and Anakinra in Children with Refractory Systemic Juvenile Idiopathic Arthritis: A Retrospective Case Series: Table 1.

Record¹,

Beukelman²,

Cron³

2011

J Rheumatol

View full text Add to dashboard Cite

“…Recent case reports demonstrated that treatment with IL-1 Ra (anakinra) led to rapid and sustained remission within a few days following the initiation of anakinra injections in patients with SOJIA who had been resistant to conventional DMARDs including TNF-blockade. [21,[58][59][60] An initial case series reported by Pascual et al [23] reported a dramatic response to IL-1 blockade among SOJIA patients with six out of nine patients treated with anakinra achieving complete remission and two having improvement in symptoms. The results obtained in this case series support the use of anakinra as second-line therapy in children with SOJIA who have failed to respond to standard therapy.…”

Section: Anakinramentioning

confidence: 99%

“…The large group of partial responders and non-responders are suggestive of pathological processes that are independent of the IL-1 pathway. [64,65] Injection site reactions (itch and/or erythema) and injection pain with daily subcutaneous medication are frequent local effects of anakinra [60,61,63] which may be so severe as to require the stoppage of medication. In the study by Zeft et al, [63] over half of the patients reported localized pain or swelling at their injection sites.…”

Section: Anakinramentioning

confidence: 99%